Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients

NCT05004675 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

166

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia
Atherosclerotic Ischemic Disease

Interventions

BIOLOGICAL: lerodalcibep
DRUG: Inclisiran

Sponsor

LIB Therapeutics LLC

Collaborators

[object Object]